Top Markets
Coin of the day
Radiopharm Theranostics Limited Radiopharm Theranostics Limited

Radiopharm Theranostics Limited

RAD
Peringkat dalam Saham #29696
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company,... Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are AvรŸ6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPยต glioblastoma diagnostic; and RAD602, a PTPยต glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Harga Saham
$0.00846342
Kapitalisasi Pasar
$20.02M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-47.56%
Negara
AU
Perdagangan Radiopharm Theranostics Limited (RAD)

Kategori

Rasio P/B untuk Radiopharm Theranostics Limited (RAD)
Rasio P/B per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Radiopharm Theranostics Limited, rasio P/B saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/B perusahaan adalah 0.
Riwayat rasio P/B untuk Radiopharm Theranostics Limited dari 2026 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
- -
KR